A 15-Year Single-Institution Retrospective Study of Primary Pancreatic Cancer Treated with Non-Ablative Palliative Radiotherapy

Randa Kamel,Tinghua Zhang,Suzanne Comino,Kristopher Dennis
DOI: https://doi.org/10.3390/cancers16050881
2024-02-23
Cancers
Abstract:We studied the use of palliative radiotherapy (RT) among patients with primary, non-curable, locally advanced pancreatic cancer. In this subset of patients, with very poor survival, various palliative RT dose fractionation schemes are used; but, in the absence of a guideline, practice patterns vary, and dose choice is mainly based on the physician's intuition. We divided the patients into three groups, according to the dose fractionation schedules received: low (A), intermediate (B), and high (C) dose groups, to study the potential differences in outcome between the different dose prescriptions. Cohort: n = 184. Median age: 69 years. Male: n = 105 (57%), female: n = 79 (43%). Stage IV: n = 117 (64%). T4: n = 127 (69%). Tumor location: head: n = 109 (59%), body: n = 37 (20%), tail: n = 25 (14%), neck: n = 11 (6%), and uncinate: n = 2 (1%). Prior systemic therapy: n = 66 (36%). Most common dose fractionations received: 20 Gy in five fractions n = 67 (36%), 30 Gy in 10 fractions n = 49 (27%), and 8 Gy in one fraction n = 23 (13%). Group A: n = 33 (18%), median overall survival (OS) 19 days (95% CI 4–33). Group B: n = 84 (46%), median OS 52 days (95% CI 43–60). Group C: n = 67 (36%), median OS 126 days (95% CI 77–174). Median days to in-field progression: Group A 59 days (range 7–109), Group B 96 days (range 19–173), and Group C 97 days (range 13–475). To our knowledge, this is the largest reported retrospective cohort of patients receiving non-ablative palliative RT to treat their primary pancreatic tumors. Most patients had metastatic disease, T4 tumors of the pancreatic head and had not received prior systemic therapy. A significant survival benefit was seen favoring the high dose/longer RT fractionation group, presumably due to appropriate patient selection rather than an RT effect. Despite the relatively short median overall survival, one fifth of the patients were found to experience an in-field progression following RT.
oncology
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to explore the application effect of non - ablative palliative radiotherapy in patients with locally advanced pancreatic cancer, especially the survival benefit and local control situation under different dose - fractionation regimens. The research background is that most pancreatic cancer patients are already in the locally advanced stage at the time of diagnosis and cannot undergo surgical resection or other radical treatments, and palliative radiotherapy is mainly used to relieve the significant symptoms caused by local tumor progression. However, there are relatively few studies on the application of palliative radiotherapy in pancreatic cancer, and there is a lack of clear dose - fractionation guidelines, resulting in the dose selection in clinical practice mainly relying on the doctor's intuition. Specifically, this study retrospectively analyzed the treatment data of pancreatic cancer patients who received non - ablative palliative radiotherapy in a single institution over a period of 15 years, aiming to: 1. **Describe the current use of non - ablative palliative radiotherapy in patients with locally advanced pancreatic cancer**: including the baseline characteristics of patients, radiotherapy dose - fractionation regimens, systemic treatment before and after treatment, etc. 2. **Evaluate the impact of different dose - fractionation regimens on the survival time and local control of patients**: Divide the patients into three groups (low - dose group, medium - dose group, and high - dose group), and compare the overall survival time and local progression time of each group. 3. **Explore the factors affecting the treatment effect**: such as the general condition of patients, tumor stage, whether they have received systemic treatment, etc., in order to provide guidance for future clinical practice. Through these research objectives, the author hopes to provide more data support and theoretical basis for optimizing the clinical application of palliative radiotherapy for pancreatic cancer.